Paul Tudor Jones’s Blueprint Medicines BPMC Stock Holding History

Paul Tudor Jones’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,800	Closed	-$231K	–	3382
2025 Q2	$231K	Buy	+1,800	New	+$187K	﹤0.01%	3022
2024 Q4	–	Sell	-7,500	Closed	-$694K	–	3030
2024 Q3	$694K	Buy	7,500 +3,800	+103%	+$377K	﹤0.01%	1835
2024 Q2	$399K	Buy	+3,700	New	+$370K	﹤0.01%	1908

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Paul Tudor Jones's BPMC Position: Q3 2025 in Review

Paul Tudor Jones sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 468,623 shares — an estimated $60.1M sold.

Paul Tudor Jones first reported a position in BPMC in Q3 2016 and held it in 16 quarters. The position peaked at $60.1M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Paul Tudor Jones reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Paul Tudor Jones sold 468,623 Blueprint Medicines shares in Q3 2025, an estimated $60.1M.
Paul Tudor Jones first reported a position in Blueprint Medicines in Q3 2016 and held it in 16 quarters.
Paul Tudor Jones's Blueprint Medicines position peaked at $60.1M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Tudor Investment Corp's 13F filing for Q3 2025, filed 14 Nov 2025.